Yann Seimbille

TL;DR: The results demonstrate the microbiota as a key factor orchestrating the overall energy homeostasis during increased demand, leading to altered intestinal gene expression promoting tissue remodeling and suppression of apoptosis.

TL;DR: Insight is provided into the microbiota-fat signaling axis and beige-fat development in health and metabolic disease and the metabolic phenotype and the browning of the subcutaneous fat are impaired by the suppression of type 2 cytokine signaling and they are reversed by recolonization of the antibiotic-treated or germ-free mice with microbes.

TL;DR: Glucose metabolic activity closely reflects response to gefitinib therapy, and may be a valuable clinical predictor, early in the course of treatment, for therapeutic responses to EGFR kinase inhibitors.

TL;DR: Increased EC plasma levels of AEA and 2-AG are associated with coronary circulatory dysfunction in obese individuals, and this observation might suggest increases inEC plasma levels as a novel endogenous cardiovascular risk factor in obesity, but needing further investigations.

TL;DR: The biodistribution of the drug analogue [18F]gefitinib suggests that it may be used to assess noninvasively the pharmacokinetics of gefitinib in patients by PET imaging, which is of clinical relevance, as insufficient intratumoral drug concentrations are considered to be a factor for resistance to gefITinib therapy.